All In Biotech

Drug Trial Radar · NCT05430373

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

A Single-arm Phase I Clinical Study of GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Planned (sponsor's estimate)

Start

May 23, 2022

Primary completion

Sep 25, 2025

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
First posted
Jun 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 participants expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes: 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).

Conditions

  • Solid Tumors, Adult

Interventions

  • GT101Biological

    Autologous tumor infiltrating lymphocyte injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Profile Measured by Grade ≥3 TEAEsTime frame: From infusion to Week 24

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The fifth medical center of the General Hospital of the Chinese people's Liberation Army

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Center

    Chongqing, Chongqing Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • West China School of Medicine/West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.